Clinical Trials
11 trialsNCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT02393690 2024-07-26
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT04354324 2024-03-15
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Zhujiang Hospital
Phase NA Unknown
NCT04964284 2023-10-23
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01837745 2023-05-17
ESTIMABL2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT00085293 2018-11-29
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Phase 2 Completed
NCT00458952 2016-07-13
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01413113 2015-11-05
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
University of Washington
Phase 1 Completed
NCT00004062 2013-12-19
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 1 Completed